Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial

NCT03588741 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped The trial was terminated as the participant withdrew from the trial.

Conditions

Haemophilia A

Interventions

DRUG: Turoctocog alfa

Sponsor

Novo Nordisk A/S